TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke
Brief Summary: The purpose of this study is to determine whether a culturally-sensitive multipronged post-discharge intervention can significantly reduce blood pressure, enhance achievement of guideline recommended targets for risk factor control, and lower recurrent vascular events in a low-income and middle-income (LMIC). The study will have 2 Phases - a qualitative phase (Phase 1) lasting less than one year involving development of the intervention through focus group methodologies and structured interviews, and a clinical trial phase (Phase 2)lasting 3 years involving a randomized trial testing the efficacy of the intervention.


Options:
A: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
B: Arm Label: Exercise Prescription + Mobile Health; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile Health, Behavioral: Exercise Prescription | Arm Label: Exercise Prescription; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Prescription | Intervention Type: BEHAVIORAL; Name: Mobile Health; Assigned to Arm(s): Exercise Prescription + Mobile Health | Intervention Type: BEHAVIORAL; Name: Exercise Prescription; Assigned to Arm(s): Exercise Prescription, Exercise Prescription + Mobile Health
C: Arm Label: text message medication reminders; Type: EXPERIMENTAL; Interventions: Behavioral: text message medication reminders | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text message medication reminders; Assigned to Arm(s): text message medication reminders
D: Arm Label: Behavioral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVES | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: THRIVES; Assigned to Arm(s): Behavioral

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Maternal Psychosocial Assessment to Care Trial (IMPACT): Intervening Early to Improve Maternal and Family Well-being.
Brief Summary: We hypothesize that the intervention will: (1) offer a feasible approach for providing mental healthcare to pregnant women and have a high level of acceptability by pregnant women and healthcare providers; (2) reduce symptoms of depression, stress, anxiety, and parenting stress; improve parenting competence, coping, and relationship adjustment compared to usual care; and (3) reduce the risk of poor maternal-infant attachment. As such, this early intervention holds promise for reducing maternal mental health morbidity and its negative influences on infants, children, and families.


Options:
A: Arm Label: Screening and CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Screening and CBT
B: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Helping to Overcome PTSD through Empowerment (HOPE) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Helping to Overcome PTSD through Empowerment (HOPE); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans
Brief Summary: The BRAVO study seeks to determine if dietary supplementation with omega-3 highly unsaturated fatty acids (omega-3 HUFAs) reduces the risk for serious suicidal behaviors, suicidal thinking, negative emotions, and symptoms associated with suicide risk, in a Veteran and non-Veteran population that is at risk for suicidal behaviors. This study seeks to evaluate the efficacy of omega-3 HUFAs among a representative population of US Veterans and non-Veterans already receiving appropriate medical care so that if successful, these results can be readily applied to broader populations in the US.


Options:
A: Arm Label: Study Juice; Type: EXPERIMENTAL; Interventions: Drug: Study Juice | Arm Label: Placebo Juice; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Juice | Intervention Type: DRUG; Name: Study Juice; Assigned to Arm(s): Study Juice | Intervention Type: DRUG; Name: Placebo Juice; Assigned to Arm(s): Placebo Juice
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2
C: Arm Label: SB-APP Psychotherapy; Type: EXPERIMENTAL; Interventions: Other: SB-APP | Arm Label: TAU treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: SB-APP; Assigned to Arm(s): SB-APP Psychotherapy | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): TAU treatment
D: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans
Brief Summary: The BRAVO study seeks to determine if dietary supplementation with omega-3 highly unsaturated fatty acids (omega-3 HUFAs) reduces the risk for serious suicidal behaviors, suicidal thinking, negative emotions, and symptoms associated with suicide risk, in a Veteran and non-Veteran population that is at risk for suicidal behaviors. This study seeks to evaluate the efficacy of omega-3 HUFAs among a representative population of US Veterans and non-Veterans already receiving appropriate medical care so that if successful, these results can be readily applied to broader populations in the US.


Options:
A: Arm Label: Study Juice; Type: EXPERIMENTAL; Interventions: Drug: Study Juice | Arm Label: Placebo Juice; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Juice | Intervention Type: DRUG; Name: Study Juice; Assigned to Arm(s): Study Juice | Intervention Type: DRUG; Name: Placebo Juice; Assigned to Arm(s): Placebo Juice
B: Arm Label: brief intervention to prevent suicide attempt; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention to prevent suicide attempt | Arm Label: standard of care; Type: OTHER; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Brief intervention to prevent suicide attempt; Assigned to Arm(s): brief intervention to prevent suicide attempt | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): standard of care
C: Arm Label: DBT Brief Suicide Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Brief Suicide Intervention | Arm Label: Relaxation Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation Training | Intervention Type: BEHAVIORAL; Name: DBT Brief Suicide Intervention; Assigned to Arm(s): DBT Brief Suicide Intervention | Intervention Type: BEHAVIORAL; Name: Relaxation Training; Assigned to Arm(s): Relaxation Training
D: Arm Label: therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): therapy | Intervention Type: OTHER; Name: Standard treatment; Assigned to Arm(s): Standard treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans
Brief Summary: The BRAVO study seeks to determine if dietary supplementation with omega-3 highly unsaturated fatty acids (omega-3 HUFAs) reduces the risk for serious suicidal behaviors, suicidal thinking, negative emotions, and symptoms associated with suicide risk, in a Veteran and non-Veteran population that is at risk for suicidal behaviors. This study seeks to evaluate the efficacy of omega-3 HUFAs among a representative population of US Veterans and non-Veterans already receiving appropriate medical care so that if successful, these results can be readily applied to broader populations in the US.


Options:
A: Arm Label: TFP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Transference-Focused Psychotherapy | Arm Label: ECP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment by experienced community psychotherapists | Intervention Type: BEHAVIORAL; Name: Transference-Focused Psychotherapy; Assigned to Arm(s): TFP | Intervention Type: BEHAVIORAL; Name: treatment by experienced community psychotherapists; Assigned to Arm(s): ECP
B: Arm Label: Study Juice; Type: EXPERIMENTAL; Interventions: Drug: Study Juice | Arm Label: Placebo Juice; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Juice | Intervention Type: DRUG; Name: Study Juice; Assigned to Arm(s): Study Juice | Intervention Type: DRUG; Name: Placebo Juice; Assigned to Arm(s): Placebo Juice
C: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care
D: Arm Label: Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention for Suicidality | Arm Label: care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Intervention for Suicidality; Assigned to Arm(s): Brief Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diagnostic Study of Performance of an Aspergillus Specific Polymerase Chain Reaction in Tissue and Pleural Effusion Samples of Immunocompromised Patients for the Diagnosis of Invasive Aspergillosis
Brief Summary: Although being a frequent and lethal complication in patients (pts) with hematologic malignancies, diagnosing invasive aspergillosis (IA) still remains a difficult issue as culture-based methods show low sensitivity especially under the current clinical practice of antifungal prophylaxis or rapid antifungal therapy. In certain clinical settings, performing biopsies for identification of the underlying infectious organism becomes important. However, as culture-based methods only yield results in a minority of patients, using non-culture-based methods like Aspergillus specific polymerase chain reaction (PCR) for detection of IA directly in clinical specimens is becoming increasingly important and might help to characterize the causative pathogen.

Therefore the performance of an established Aspergillus-specific nested PCR in biopsies, re-section material or pleural effusions is evaluated.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ORAL VORICONAZOLE and IV Amphotericin B | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ORAL VORICONAZOLE and IV Amphotericin B | Intervention Type: DRUG; Name: ORAL VORICONAZOLE and IV Amphotericin B; Assigned to Arm(s): 1, 2
B: Arm Label: Standard diagnostic strategy of culture and histology; Type: ACTIVE_COMPARATOR; Interventions: Other: Culture and histology | Arm Label: Aspergillus galactomannan and PCR directed; Type: EXPERIMENTAL; Interventions: Other: Aspergillus galactomannan and PCR | Intervention Type: OTHER; Name: Culture and histology; Assigned to Arm(s): Standard diagnostic strategy of culture and histology | Intervention Type: OTHER; Name: Aspergillus galactomannan and PCR; Assigned to Arm(s): Aspergillus galactomannan and PCR directed
C: Arm Label: Proven/Probable IA Patients; Type: N/A; Interventions: N/A | Arm Label: possible/No IA Patients; Type: N/A; Interventions: N/A
D: Arm Label: High Risk Oncohematological Patients; Type: N/A; Interventions: Procedure: Aspergillus PCR technique, Procedure: Aspergillus AGA technique | Intervention Type: PROCEDURE; Name: Aspergillus PCR technique; Assigned to Arm(s): High Risk Oncohematological Patients | Intervention Type: PROCEDURE; Name: Aspergillus AGA technique; Assigned to Arm(s): High Risk Oncohematological Patients

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome
Brief Summary: Currently, there is no proven effective pharmacologic treatment available for patients with the acute respiratory distress syndrome (ARDS). Mesenchymal stem cells have been shown to be effective in treating several inflammatory diseases. The main purpose of this study is to assess the safety of allogeneic adipose-derived mesenchymal stem cells in patients with ARDS.


Options:
A: Arm Label: No dexamethasone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone
B: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Human Mesenchymal Stromal Cells (hMSCs); Type: EXPERIMENTAL; Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells | Arm Label: Plasma-Lyte A (placebo); Type: PLACEBO_COMPARATOR; Interventions: Biological: Plasma-Lyte A | Intervention Type: BIOLOGICAL; Name: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells; Assigned to Arm(s): Human Mesenchymal Stromal Cells (hMSCs) | Intervention Type: BIOLOGICAL; Name: Plasma-Lyte A; Assigned to Arm(s): Plasma-Lyte A (placebo)
D: Arm Label: Mesenchymal stem cell arm; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stem cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mesenchymal stem cells; Assigned to Arm(s): Mesenchymal stem cell arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis
Brief Summary: The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to) Asacol™(1).

(1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.


Options:
A: Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): N/A
B: Arm Label: Mesalazine once/day; Type: EXPERIMENTAL; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Arm Label: Mesalazine twice/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine slow-release granules, Drug: Mesalazine liquid enema | Intervention Type: DRUG; Name: Mesalazine slow-release granules; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day | Intervention Type: DRUG; Name: Mesalazine liquid enema; Assigned to Arm(s): Mesalazine once/day, Mesalazine twice/day
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: mesalazine | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: mesalazine; Assigned to Arm(s): B
D: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis
Brief Summary: The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to) Asacol™(1).

(1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.


Options:
A: Arm Label: TP05 (Mesalazine) 1600mg; Type: EXPERIMENTAL; Interventions: Drug: TP05 | Arm Label: Asacol 400 mg (Tillotts Pharma); Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg | Intervention Type: DRUG; Name: TP05; Assigned to Arm(s): TP05 (Mesalazine) 1600mg | Intervention Type: DRUG; Name: Asacol 400 mg; Assigned to Arm(s): Asacol 400 mg (Tillotts Pharma)
B: Intervention Type: DRUG; Name: SPD476 (mesalazine); Assigned to Arm(s): N/A
C: Arm Label: Mesalamine (Asacol) Once-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Once-Daily | Arm Label: Mesalamine (Asacol) Twice-Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalamine Twice-Daily | Intervention Type: DRUG; Name: Mesalamine Once-Daily; Assigned to Arm(s): Mesalamine (Asacol) Once-Daily | Intervention Type: DRUG; Name: Mesalamine Twice-Daily; Assigned to Arm(s): Mesalamine (Asacol) Twice-Daily
D: Arm Label: Increase mesalamine dose by 2.4g/day; Type: EXPERIMENTAL; Interventions: Drug: mesalamine | Arm Label: Maintain mesalmine dose; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: mesalamine; Assigned to Arm(s): Increase mesalamine dose by 2.4g/day

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Brief Summary: This is a Phase 2, randomized, placebo-controlled multicenter study, which will be conducted in 2 parts. The study duration for each subject will be approximately 33 weeks and will include 25 study visits.


Options:
A: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betahistine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Betahistine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): 2
C: Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Samidorphan (Low Dose), Drug: Olanzapine | Arm Label: Medium Dose; Type: EXPERIMENTAL; Interventions: Drug: Samidorphan (Medium Dose), Drug: Olanzapine | Arm Label: High Dose; Type: EXPERIMENTAL; Interventions: Drug: Samidorphan (High Dose), Drug: Olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Olanzapine | Intervention Type: DRUG; Name: Samidorphan (Low Dose); Assigned to Arm(s): Low Dose | Intervention Type: DRUG; Name: Samidorphan (Medium Dose); Assigned to Arm(s): Medium Dose | Intervention Type: DRUG; Name: Samidorphan (High Dose); Assigned to Arm(s): High Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): High Dose, Low Dose, Medium Dose, Placebo
D: Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: lifestyle intervention; Assigned to Arm(s): N/A

Answer: C